Literature DB >> 30890595

PD-1 blockade as bridge to allogeneic stem cell transplantation in relapsed/refractory Hodgkin lymphoma patients: a retrospective single center case series.

Beatrice Casadei1, Alessandro Broccoli1, Vittorio Stefoni1, Cinzia Pellegrini1, Miriam Marangon1, Alice Morigi1, Laura Nanni1, Ginevra Lolli1, Matteo Carella1, Lisa Argnani1, Michele Cavo1, Pier Luigi Zinzani2.   

Abstract

Entities:  

Year:  2019        PMID： 30890595      PMCID： PMC6821632          DOI： 10.3324/haematol.2019.215962

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  10 in total

Review 1.  Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma: a systematic review and meta-analysis.

Authors:  A Rashidi; M Ebadi; A F Cashen
Journal:  Bone Marrow Transplant       Date:  2016-01-04       Impact factor: 5.483

2.  Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma.

Authors:  Robert Chen; Ajay K Gopal; Scott E Smith; Stephen M Ansell; Joseph D Rosenblatt; Kerry J Savage; Joseph M Connors; Andreas Engert; Emily K Larsen; Dirk Huebner; Abraham Fong; Anas Younes
Journal:  Blood       Date:  2016-07-18       Impact factor: 22.113

3.  Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma.

Authors:  Reid W Merryman; Haesook T Kim; Pier Luigi Zinzani; Carmelo Carlo-Stella; Stephen M Ansell; Miguel-Angel Perales; Abraham Avigdor; Ahmad S Halwani; Roch Houot; Tony Marchand; Nathalie Dhedin; Willy Lescaut; Anne Thiebaut-Bertrand; Sylvie François; Aspasia Stamatoullas-Bastard; Pierre-Simon Rohrlich; Hélène Labussière Wallet; Luca Castagna; Armando Santoro; Veronika Bachanova; Scott C Bresler; Amitabh Srivastava; Harim Kim; Emily Pesek; Marie Chammas; Carol Reynolds; Vincent T Ho; Joseph H Antin; Jerome Ritz; Robert J Soiffer; Philippe Armand
Journal:  Blood       Date:  2017-01-10       Impact factor: 22.113

4.  Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.

Authors:  Robert Chen; Pier Luigi Zinzani; Michelle A Fanale; Philippe Armand; Nathalie A Johnson; Pauline Brice; John Radford; Vincent Ribrag; Daniel Molin; Theodoros P Vassilakopoulos; Akihiro Tomita; Bastian von Tresckow; Margaret A Shipp; Yinghua Zhang; Alejandro D Ricart; Arun Balakumaran; Craig H Moskowitz
Journal:  J Clin Oncol       Date:  2017-04-25       Impact factor: 44.544

5.  Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

Authors:  Michael R Green; Stefano Monti; Scott J Rodig; Przemyslaw Juszczynski; Treeve Currie; Evan O'Donnell; Bjoern Chapuy; Kunihiko Takeyama; Donna Neuberg; Todd R Golub; Jeffery L Kutok; Margaret A Shipp
Journal:  Blood       Date:  2010-07-13       Impact factor: 22.113

6.  Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant.

Authors:  Sally Arai; Michelle Fanale; Sven DeVos; Andreas Engert; Tim Illidge; Peter Borchmann; Anas Younes; Franck Morschhauser; Alex McMillan; Sandra J Horning
Journal:  Leuk Lymphoma       Date:  2013-06-05

Review 7.  Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evil.

Authors:  Charles Herbaux; Reid Merryman; Steven Devine; Philippe Armand; Roch Houot; Franck Morschhauser; Bradley Haverkos
Journal:  Blood       Date:  2018-05-02       Impact factor: 22.113

8.  PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma.

Authors:  Ryo Yamamoto; Momoko Nishikori; Toshio Kitawaki; Tomomi Sakai; Masakatsu Hishizawa; Masaharu Tashima; Tadakazu Kondo; Katsuyuki Ohmori; Masayuki Kurata; Takamasa Hayashi; Takashi Uchiyama
Journal:  Blood       Date:  2008-01-18       Impact factor: 22.113

9.  The PD-1 Axis Enforces an Anatomical Segregation of CTL Activity that Creates Tumor Niches after Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  David Michonneau; Pervinder Sagoo; Béatrice Breart; Zacarias Garcia; Susanna Celli; Philippe Bousso
Journal:  Immunity       Date:  2016-01-12       Impact factor: 31.745

10.  Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.

Authors:  Philippe Armand; Andreas Engert; Anas Younes; Michelle Fanale; Armando Santoro; Pier Luigi Zinzani; John M Timmerman; Graham P Collins; Radhakrishnan Ramchandren; Jonathon B Cohen; Jan Paul De Boer; John Kuruvilla; Kerry J Savage; Marek Trneny; Margaret A Shipp; Kazunobu Kato; Anne Sumbul; Benedetto Farsaci; Stephen M Ansell
Journal:  J Clin Oncol       Date:  2018-03-27       Impact factor: 44.544
  10 in total
  1 in total

Review 1.  Emerging Therapies in Relapsed and Refractory Hodgkin Lymphoma: What Comes Next After Brentuximab Vedotin and PD-1 Inhibition?

Authors:  Tamer Othman; Alex Herrera; Matthew Mei
Journal:  Curr Hematol Malig Rep       Date:  2021-01-06       Impact factor: 3.952
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.